ArticleScientific reports2025
An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Molecular and regulatory aspects of EPA: a Nakaseomyces glabratus epithelial adhesin.Archives of microbiology · 2026Review
- Clinical Utility of the Paed-EQUAL Candida Score in Paediatric Candidemia: A Real-World Cohort Study.Mycoses · 2026Observational
- Pediatric candidemia epidemiology and antifungal susceptibility profiles reported by the ISPED program in China, 2016-2024.Antimicrobial agents and chemotherapy · 2026Article
- Retrospective analysis of the epidemiological characteristics, risk factors, survival rate, and drug resistance of candidemia and construction of a logistic regression prediction model (2013-2024).BMC infectious diseases · 2026Article
- Clinical Determinants of 30-Day Mortality in Candidemia: Antifungal Susceptibility and Treatment Patterns in a 10-Year Cohort.Antibiotics (Basel, Switzerland) · 2026Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- High co-infection burden and ICU-specific pathogen profiles in pediatric Candida albicans respiratory infections: a large-scale tNGS analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Development of Melting-Curve-Based Real-Time PCR for Differentiating Medically ImportantInternational journal of molecular sciences · 2025Article
- Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005-2025).Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- The Influence of the Seasonal Variability ofAntibiotics (Basel, Switzerland) · 2025Article
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Epidemiology risk factors and antifungal resistance patterns ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidiasis poses a significant threat to human health, especially in immunocompromised patients. However, there is a paucity of epidemiological data concerning the prevalence of candidiasis in developing regions of China. We conducted a retrospective study on patients positive for Candida infections in a tertiary care hospital in Shantou, China, to identify the clinical characteristics and risk factors for candidiasis. Of 5,095 cases of candidiasis, 489 (9.59%) were candidemia infections. Candida albicans (n = 230, 47.0%) was the predominant species identified among all patients. Non-albicans Candida (NAC) was more prevalent in adult patients, while Candida glabrata was slightly more frequent in pediatric patients (n = 10, 14.7%). Pulmonary diseases (n = 200, 47.8%) were the most common underlying comorbidities in adult patients (n = 25, 35.2%). Thrombocytopenia was the only laboratory finding higher in adult patients than in pediatric patients. Respiratory dysfunction, the presence of a central venous catheter, septic shock, and thrombocytopenia were independent risk factors for candidemia-related 30-day mortality. Amphotericin B exhibited high efficacy (100%), and itraconazole exhibited the lowest efficacy against all tested Candida isolates. C. glabrata had a lower susceptibility to azole, although this was not statistically significant. The epidemiological data on candidiasis, specifically candidemia in pediatric and adult patients, varied regarding the prevalence of Candida species and associated risk factors. This study provides guidance for prescribing the appropriate therapy and yields insights into the susceptibility patterns of different Candida isolates to antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.